Aldeyra Therapeutics (ALDX) Projected to Post Quarterly Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Aldeyra Therapeutics to post earnings of ($0.25) per share and revenue of ($0.80) million for the quarter.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30). On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock traded up $0.01 on Friday, hitting $2.66. 1,375,003 shares of the stock were exchanged, compared to its average volume of 717,773. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $158.83 million, a PE ratio of -2.83 and a beta of 0.94. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20. The firm's 50 day moving average is $4.76 and its two-hundred day moving average is $5.05.

Insiders Place Their Bets

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company's stock, valued at $8,343,708.42. The trade was a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 8.50% of the company's stock.

Analysts Set New Price Targets

ALDX has been the subject of several research analyst reports. BTIG Research dropped their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, April 4th.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.